United States · FDA National Drug Code directory

FLUZONE HD TIV SH 2026

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
49281-016_602db593-4e91-45de-ac0f-6a8b0312341a
Product NDC
49281-016
Form
INJECTION, SUSPENSION
Composition / generic term
INFLUENZA A VIRUS A/SWITZERLAND/6849/2025 IVR-278 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/SINGAPORE/GP20238/2024 IVR-277 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED), and INFLUENZA B VIRUS B/MICHIGAN/01/2021 ANTIGEN (FORMALDEHYDE INACTIVATED)
Labeler
Sanofi Vaccines US Inc.
Marketing category
BLA
Marketing start / end (source format)
20260220 / 20261231

Source-listed ingredients

  • INFLUENZA A VIRUS A/SWITZERLAND/6849/2025 IVR-278 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED) — 60 ug/.5mL
  • INFLUENZA A VIRUS A/SINGAPORE/GP20238/2024 IVR-277 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED) — 60 ug/.5mL
  • INFLUENZA B VIRUS B/MICHIGAN/01/2021 ANTIGEN (FORMALDEHYDE INACTIVATED) — 60 ug/.5mL

These values do not establish equivalence or a dose recommendation.

Packages

  • 10 SYRINGE, GLASS in 1 PACKAGE (49281-016-50) / .5 mL in 1 SYRINGE, GLASS (49281-016-88) · 49281-016-50

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →